NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









OMEICOS Therapeutics

OMEICOS Therapeutics

Private
BerlinHealthcare & Life Scienceshttps://omeicos.com/

Last Round

Grant

Jun 21, 2023

Total Funding Raised

$42.26M

Company Overview

OMEICOS Therapeutics is a biopharmaceutical company that develops first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular, ophthalmic, and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Clinical Trials, Drug Discovery, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

small molecule therapeuticsmitochondrial diseasefirst-in-class drugsrare disease therapeuticsorphan drugsPrimary Mitochondrial DiseasesPMDclinical-stage biotechomega-3 metabolite analogmitochondrial dysfunctionoral therapeuticsanti-inflammatory drugsbiotech licensingepoxyeicosanoid analoguesatrial fibrillation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

OMEICOS Therapeutics Comparables

Compare OMEICOS Therapeutics with similar companies based on industry and business-model similarity.

OMEICOS Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Khondrion
86%
Abliva AB (publ)
80%
Reneo Pharmaceuticals
78%

OMEICOS Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 21, 2023
Series CNov 2, 2018
Series B ExtensionOct 4, 2017
GrantJun 7, 2017
Series BMar 1, 2017
Series A
Apr 15, 2015

Key People

Founding team and executive leadership

Robert Fischer

Chief Executive Officer, Managing Director, Chief Scientific Officer

Executive Team

OMEICOS Therapeutics Investors

Notable investors and investment history

OMEICOS Therapeutics investors
InvestorRounds
Federal Ministry of Education and ResearchGrant
ForbionSeries C
IBB VenturesSeries B Extension, Series B, Series A, Seed, Series C
Bundesministerium für Bildung und ForschungGrant
Remiges VenturesSeries B, Series C, Series B Extension
AscenionSeries B, Grant
Vesalius Biocapital PartnersSeries B Extension, Series C, Series B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 25, 2026

    Grew 80% QoQ from 5 to 9 employees.

  • Jun 21, 2023

    Received $3M from Bundesministerium für Bildung und Forschung.

OMEICOS Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

OMEICOS Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about OMEICOS Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBerlin
Employee Range9
Year Founded2013
Last FundingJun 21, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.